Eribulin Mesylate in the management of metastatic breast cancer and other solid cancers: a drug review
Polastro, L.; Aftimos, P.G.; Awada, A. (2014). Eribulin Mesylate in the management of metastatic breast cancer and other solid cancers: a drug review. Expert Review of Anticancer Therapy 14(6): 649-665. https://dx.doi.org/10.1586/14737140.2014.920693
In: Expert Review of Anticancer Therapy. TAYLOR & FRANCIS LTD: Abingdon. ISSN 1473-7140; e-ISSN 1744-8328, more
|  |
| Author keywords |
breast cancer; chemotherapy; eribulin; review; solid tumor |
| Authors | | Top |
- Polastro, L.
- Aftimos, P.G.
- Awada, A.
|
|
|
| Abstract |
In the new era of precision' cancer medicine, new drug development has shifted from cytotoxic chemotherapy to molecularly targeted agents. Eribulin mesylate, a microtubule-destabilizing agent, is the only classical' cytotoxic agent approved for the treatment of breast cancer in the last 7 years. This synthetic analogue of halichondrin B, isolated from the marine sponge Halicondria Okaida', was responsible for prolonging overall survival of heavily pretreated metastatic breast cancer patients in a large Phase III trial. Eribulin is now under clinical development in earlier settings such as the neo-adjuvant and adjuvant settings. Furthermore, its unique mechanism of action and the absence of cross-resistance with taxanes have led to the design of clinical trials in multiple indications: bladder cancer, lung cancer, prostate cancer... The main adverse events are neutropenia, fatigue and peripheral neuropathy. |
|
